24.4 C
New York
Friday, June 12, 2026

Tag: option

Doppler Brings Secrets Management On-prem for Full Control

All the simplicity of Doppler within your own infrastructure.SAN FRANCISCO, June 8, 2026 /PRNewswire/ -- Run Doppler on your termsDoppler announced today the launch of...

Agent Governance Platform from Ares® Networks Now Available in the Microsoft Marketplace

Microsoft Azure customers worldwide can now discover and deploy the Ares® Networks Agent Governance Platform through Microsoft Marketplace, accessing trusted solutions that accelerate innovation...

Helius Minerals Provides Status Update on Serra Pelada Project Acquisition Transaction

VANCOUVER, BC, June 8, 2026 /CNW/ - Helius Minerals Limited ("Helius" or the "Company") (TSXV: HHH) is pleased to provide an update on the status...

Titiminas Silver Commences Drill Program at the Madre Sierra Silver Mine, Peru

4,000-metre Packsack underground program underway concurrent with 15,500-metre HQ diamond drill programLIMA, Peru, June 8, 2026 /CNW/ - Titiminas Silver Inc. (TSXV: TITI) ("Titiminas"...

Decisions taken by Suominen Corporation’s Extraordinary General Meeting

Suominen Corporation’s stock exchange release on June 8, 2026, at 10:30 a.m. (EEST)

Arrivia and KrisFlyer Expand Partnership to Launch Cruise Redemptions with Miles

SINGAPORE, June 8, 2026 /PRNewswire/ -- arrivia and KrisFlyer, the lifestyle rewards programme of the Singapore Airlines Group, are elevating member benefits with the...

Toobit Adds XLM to Fixed Earn Series with Limited-Time 60% APR

GEORGE TOWN, Cayman Islands, June 08, 2026 (GLOBE NEWSWIRE) -- Toobit, the award-winning global cryptocurrency exchange, today announces the addition of Stellar (XLM) to its high-yield Fixed Earn series, offering traders an opportunity to capture 60% APR on their staked assets.

Dayspring Pharma Announces Positive Topline Results from Phase II Clinical Trial of CG2001 for the Treatment of Androgenetic Alopecia (AGA)

SEOUL, South Korea, June 8, 2026 /PRNewswire/ -- Dayspring Pharma, a clinical-stage biotechnology company focused on innovative dermatology therapies, announced the first public disclosure of...

Dayspring Pharma Announces Positive Topline Results from Phase II Clinical Trial of CG2001 for the Treatment of Androgenetic Alopecia (AGA)

SEOUL, South Korea, June 7, 2026 /PRNewswire/ -- Dayspring Pharma, a clinical-stage biotechnology company focused on innovative dermatology therapies, announced the first public disclosure of...

Dayspring Pharma Announces Positive Topline Results from Phase II Clinical Trial of CG2001 for the Treatment of Androgenetic Alopecia (AGA)

SEOUL, South Korea, June 7, 2026 /CNW/ -- Dayspring Pharma, a clinical-stage biotechnology company focused on innovative dermatology therapies, announced the first public disclosure of...

Australian Retirees Seek Reliable Monthly Income From Global Private Credit as Inflation Bites and TermPlus Targets Up To 8.50%* Per Annum

Sydney, Australia, June 07, 2026 (GLOBE NEWSWIRE) -- With annual inflation at 4.6% in the year to March 2026 and roughly 4.4 million Australians now aged 65 and over, retirees face a sharpening challenge: turning a lifetime of savings into income that keeps pace with the rising cost of groceries, fuel and everyday essentials. The pressure is compounded by longevity, with many Australians spending two or even three decades in retirement, and by a shift in mindset that retirement itself demands. In the accumulation years, investors can ride out market volatility and recover losses over time; in the drawdown phase, with shorter horizons and less capacity to recoup losses, the priority moves to predictable income and preserving purchasing power. To learn more visit https://termplus.com.au/insights-news/news/turning-savings-into-reliable-monthly-income-in-retirement/

LENZ Therapeutics Announces Everest Medicines Acquired Rights to Develop and Commercialize VIZZ® (LNZ100) in Greater China

The New Drug Application for LNZ100 in China was submitted September 2025 with approval anticipated in Q1 2027
The New Drug Application for LNZ100 in China was submitted September 2025 with approval anticipated in Q1 2027

Antag Therapeutics presents positive Phase 1 results at the 2026 Scientific Sessions of the American Diabetes Association for AT7687, a first-in-class GIPR antagonist

Copenhagen, Denmark, 7 June 2026 – Antag Therapeutics (“Antag” or “the Company”), advancing personalized and flexible obesity treatment through GIP receptor antagonism, today presented key Phase 1 and preclinical data for AT7687 at the 2026 Scientific Sessions of the American Diabetes Association®, held in New Orleans, Louisiana from June 5-8, 2026.

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsOption